Literature DB >> 16330929

Pyothorax-associated lymphoma: a lymphoma developing in chronic inflammation.

Katsuyuki Aozasa1, Tetsuya Takakuwa, Shin-ichi Nakatsuka.   

Abstract

Pyothorax-associated lymphoma (PAL) is a non-Hodgkin lymphoma of exclusively B-cell phenotype developing in the pleural cavity of patients after more than 20-year history of pyothorax resulting from an artificial pneumothorax for the treatment of pulmonary tuberculosis or tuberculous pleuritis. The most common symptoms on admission are chest pain and fever. Serum neuron-specific enolase level suggesting a diagnosis of small cell lung cancer is occasionally elevated. Histologically PAL usually shows a diffuse proliferation of large cells of B-cell type (diffuse large B-cell lymphoma [DLBL]). In PAL cells, representative B-cell markers other than CD20 are frequently negative with aberrant expression of T-cell markers such as CD2. A gene expression profile of PAL is distinct from nodal DLBL in its higher expression level of interferon-inducible genes. PAL is strongly associated with Epstein-Barr virus (EBV) infection with expression of EBV latent genes such as EBNA-2, LMP-1, together with EBNA-1. Taken together, PAL is a distinct entity both in its clinicopathologic presentation as well as its gene expression profile. Use of an artificial pneumothorax, EBV infection, and cytokines and reactive oxygen species produced in longstanding pyothorax might be important factors for PAL development.

Entities:  

Mesh:

Year:  2005        PMID: 16330929     DOI: 10.1097/01.pap.0000194627.50878.02

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  18 in total

Review 1.  Current status of treatment for primary effusion lymphoma.

Authors:  Seiji Okada; Hiroki Goto; Mihoko Yotsumoto
Journal:  Intractable Rare Dis Res       Date:  2014-08

Review 2.  Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification.

Authors:  Elaine S Jaffe; Stefania Pittaluga
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

3.  Acute onset pyothorax-associated lymphoma (PAL) with inflammatory features.

Authors:  Tadashi Terada
Journal:  Int J Clin Exp Pathol       Date:  2012-02-12

4.  The evolution of Epstein-Barr virus inferred from the conservation and mutation of the virus glycoprotein gp350/220 gene.

Authors:  Asako Kawaguchi; Kyosuke Kanai; Yukio Satoh; Chizu Touge; Keiko Nagata; Takeshi Sairenji; Yoshitsugu Inoue
Journal:  Virus Genes       Date:  2009-01-20       Impact factor: 2.332

Review 5.  The histological classification of diffuse large B-cell lymphomas.

Authors:  Yi Xie; Stefania Pittaluga; Elaine S Jaffe
Journal:  Semin Hematol       Date:  2015-01-17       Impact factor: 3.851

Review 6.  Role of bacteria in oncogenesis.

Authors:  Alicia H Chang; Julie Parsonnet
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

Review 7.  The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.

Authors:  Elias Campo; Steven H Swerdlow; Nancy L Harris; Stefano Pileri; Harald Stein; Elaine S Jaffe
Journal:  Blood       Date:  2011-02-07       Impact factor: 22.113

Review 8.  The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification.

Authors:  Madhu P Menon; Stefania Pittaluga; Elaine S Jaffe
Journal:  Cancer J       Date:  2012 Sep-Oct       Impact factor: 3.360

9.  EBV-Positive B-Cell Proliferations of Varied Malignant Potential: 2015 SH/EAHP Workshop Report-Part 1.

Authors:  Yasodha Natkunam; John R Goodlad; Amy Chadburn; Daphne de Jong; Dita Gratzinger; John K C Chan; Jonathan Said; Elaine S Jaffe
Journal:  Am J Clin Pathol       Date:  2017-02-01       Impact factor: 2.493

10.  A Unique "Composite" PTLD with Diffuse Large B-Cell and T/Anaplastic Large Cell Lymphoma Components Occurring 17 Years after Transplant.

Authors:  Kristin La Fortune; Dahua Zhang; Gordana Raca; Erik A Ranheim
Journal:  Case Rep Hematol       Date:  2013-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.